Increasing the daily dose of recombinant follicle stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation-Reference-Cited by-同舟云学术

Increasing the daily dose of recombinant follicle stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation

Published:2000-01 Issue:1 Volume:15 Page:29-35
ISSN:1460-2350
Container-title:Human Reproduction
language:en
Short-container-title:

Author:

Out Henk J.,Braat Didi D.M.,Lintsen Bea M.E.,Gurgan Timur,Bukulmez Orhan,Gökmen Oya,Keles Gürhan,Caballero Pedro,González José M.,Fábregues Francisco,Balasch Juan,Roulier Roger

Publisher

Oxford University Press (OUP)

Subject

Obstetrics and Gynaecology,Rehabilitation,Reproductive Medicine

Link

http://academic.oup.com/humrep/article-pdf/15/1/29/

Reference20 articles.

1. Albano, C., Smitz, J., Camus, M. et al. (1996) Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix). Hum. Reprod., 11, 2114–2118.

2. Ben Rafael, Z., Benadiva, C.A., Ausmanas, M. et al. (1987) Dose of human menopausal gonadotropin influences the outcome of an in vitro fertilization program. Fertil. Steril., 48, 964–968.

3. Coelingh Bennink, H.J.T., Fauser, B.C.J.M., Out, H.J. for the European Puregon Collaborative Anovulation Study Group (1998) Recombinant FSH (Puregon) is more efficient than urinary FSH (Metrodin) in clomiphene-resistant normogonadotropic chronic anovulatory women: a prospective, multicenter, assessor-blind, randomised, clinical trial. Fertil. Steril., 69, 19–25.

4. CPMP Working Party on Efficacy of Medicinal Products (1990) Good Clinical Practice for trials on medicinal products in the European Community. Pharmacol. Toxicol., 67, 361–372.

5. Devroey, P., Tournaye, H., Van Steirteghem, A. et al. (1998) The use of a 100 IU starting dose of recombinant FSH (Puregon®) in in-vitro fertilization. Hum. Reprod., 13, 565–566.

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical factors associated with unexpected poor or suboptimal response in Poseidon criteria patients;Reproductive BioMedicine Online;2024-07

2. Significance of serum AMH and antral follicle count discrepancy for the prediction of ovarian stimulation response in Poseidon criteria patients;Journal of Assisted Reproduction and Genetics;2024-02-15

3. Nonlinear relationship between gonadotropin total dose applied and live birth rates in non-PCOS patients: a retrospective cohort study;Scientific Reports;2024-01-17

4. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI);Cochrane Database of Systematic Reviews;2024-01-04

5. High initial FSH dosage reduces the number of available cleavage-stage embryos in a GnRH-antagonist protocol: Real-world data of 8,772 IVF cycles from China;Frontiers in Endocrinology;2022-10-17